By a News Reporter-Staff News Editor at Investment Weekly News A patent application by the inventors Seifert, Jody; Suh, Sean, filed on April 25, 2018, was made available online on August 23, 2018, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application is assigned to Globus Medical I
Pune, India 09/14/2018 The report "Global Dental Market: Industry Analysis& Outlook" analyzes the development of this market, with specific focus on the US, European and Asian dental markets. Access Full Copy of Global Dental Market: Industry Analysis& Outlook spread across 115 Pages, Profiling 3 Companies and Supported with 76 charts is now
AstraZeneca and its global biologics research and development arm MedImmune announced on Friday that the US Food and Drug Administration has approved Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukaemia. The FTSE 100 drugmaker said the approval was for those patients who had received at least two prior syste
Beth Israel Deaconess Hospital-Plymouth announced Sept. 12 its opposition to ballot question 1, which would mandate rigid nurse staffing ratios throughout the state. "Beth Israel Deaconess Hospital-Plymouth is nationally-recognized as a top hospital for patient safety and quality with a four-star rating from the Centers for Medicare and Medicaid a
INGELHEIM AM RHEIN, Germany, Sept. 13 Boehringer Ingelheim, a pharmaceutical company, issued the following news release:. Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. Boehringer Ingelheim and ViraTherapeutics are.
By a News Reporter-Staff News Editor at Marketing Weekly News Celltrion, Inc. announced that the company has completed Phase 3 clinical trial for' Remsima SC', the subcutaneous version of Remsima , the autoimmune disease therapeutic antibody biosimilar of infliximab, with the preparation for filing a Marketing Authorization Application to the E
-Clinician researchers at ChenMed and the University of Miami today reported findings showing that Medicare-eligible seniors with Medicare Advantage insurance enjoy substantively better health outcomes when they benefit from high-intensity care that encourages frequent direct person-to-person interaction between patients and their primary...
A new report by visiongain forecasts the world market for colorectal cancer drugs will reach $10.75 billion in 2019. Visiongain is a business information publisher and consultancy in London, UK. Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: "The colorectal cancer drugs market will continue to expand at a steady pace, owing to
Caroline Eggerding, MD, Division Head, Pediatric Neurology and Development led a research team at Cooper University Health Care which was instrumental in conducting clinical trials for a ground-breaking new drug approved earlier this year to treat Phenylketonuria, a rare genetic disorder. We are excited that medical science has found a new treatmen
Sept. 15 SANTA CRUZ One of the terms of a mega-merger between Dominican Hospital parent Dignity Heath and Catholic Health Initiatives is status quo operation of Dominican Hospital, its emergency services, staff and facilities for five years post-agreement. Dominican Hospital, a 222- bed facility, reported $432 million in operating revenue in fi
Reports by the Federal Trade Commission and the Food and Drug Administration also show that generic competition saves billions of dollars annually, cutting the price of name-brand drugs by more than 85 percent. Patrick Leahy, D- Vt., and Chuck Grassley, R- Iowa, but the number of senators signing on as co-sponsors has been growing, including Sen.
EpimAb Biotherapeutics, an emerging Shanghai- based biopharmaceutical company specializing in bispecific antibodies, announced today that it has filed an IND for its most advanced therapeutic development candidate EMB01. The applications were simultaneously submitted to the U.S. Food and Drug Administration and the National Medical Products...
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The U.S. Food and Drug Administration today approved a device intended to treat acute coronary artery perforations, or tears in the blood vessels of the heart. "An acute coronary artery perforation is a rare, but potentially life-thre
Acorda Therapeutics, Inc. announced that the FDA has extended the Prescription Drug User Fee Act goal date for its review of the New Drug Application of Inbrija from October 5, 2018 to January 5, 2019. We look forward to continuing our constructive dialogue with FDA, said Ron Cohen, M.D., Acordas president and CEO. The FDA accepted Acordas NDA for
The US Food and Drug Administration has revealed plans to support the Pediatric Device Consortia programme aimed at the development, production and distribution of paediatric medical devices. Of the total funds, $1 m will be used for the Real World Evidence Demonstration Project. FDA commissioner Scott Gottlieb said: We know that developing product
Ironwood Pharmaceuticals announced that praliciguat for the treatment of patients with HF with preserved ejection fraction has been granted fast track designation by the FDA. Praliciguat is an investigational soluble guanylate cyclase simulator that is administered orally, according to a press release from the company. An ever-increasing number of.
U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants. The Food and Drug Administration said it would hold the meeting even as its officials
Under the plan, hospitals would pay a flat rate for access to a certain number of doses for an antibiotic, FDA Commissioner Scott Gottlieb said. FDA is trying to tackle the lack of incentives for drug companies to create medicines by creating a more stable stream of funding from hospitals back to the companies. "Large pharmaceutical companies have
In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., has initiated a Phase 1 clinical trial of a new first-in-class cancer drug candidate, a small molecule compound discovered by Prof. Waldemar Priebe at The Universi
Albany, NY 09/14/2018 A comprehensive research report created through extensive primary research and secondary research, the report aims to present the analysis of Global Gastrointestinal Endoscopy Devices Market By Product Type, By End User, By Region and By Country. According to Azoth Analytics research report "Global Gastrointestinal Endos
Albany, NY 09/14/2018 This report studies the global market size of Medical Implants in key regions like North America, Europe, Asia Pacific, Central& South America and Middle East& Africa, focuses on the consumption of Medical Implants in these regions. This research report categorizes the global Medical Implants market by top players/brands
An FDA press release billed the operation as "the largest coordinated enforcement effort in the FDA' s history." In a Wednesday speech at FDA headquarters, FDA Commissioner Scott Gottlieb said there are "clear signs that youth use of electronic cigarettes has reached an epidemic proportion, and we must adjust certain aspects of our comprehensive st
The Subcommittee on Health will hold a hearing on Thursday, September 13, 2018, at 1:15 p.m. in 2322 Rayburn House Office Building. *Michael Robertson, Chief Medical Officer, Covenant Health Partners;. *Michael Weinstein, President, Digestive Health Physicians Association;.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase 1 a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, at.